What is Synagis, and what is it used for?
Synagis is the brand name for palivizumab, a medicine given to help prevent serious respiratory syncytial virus (RSV) illness in high-risk infants and young children [1]. It is not a routine “RSV vaccine” in the usual sense; it is a preventive antibody given as injections during RSV season [1].
Who typically gets Synagis (palivizumab)?
Synagis is used for infants/children considered at higher risk for severe RSV disease. The specific eligibility depends on age and risk factors and is set by local health guidance and prescribing information [1].
How is Synagis given, and when?
Synagis is administered as a series of injections during RSV season [1]. Dosing schedules are based on patient characteristics and prescribing guidance [1]. It is used to reduce the likelihood of hospitalization from RSV rather than to treat an RSV infection after it starts [1].
What are the side effects people ask about?
Like other injectable medicines, Synagis can cause side effects related to administration and the immune system. Commonly discussed issues include reactions around the injection site, along with general medication side effects [1]. Serious reactions are less common but can occur, and clinical guidance typically advises monitoring during and after dosing [1].
How effective is Synagis at preventing RSV hospitalization?
Synagis is used because clinical experience shows it can reduce the risk of RSV-related lower respiratory tract disease and hospitalization in high-risk children [1].
Is Synagis the same as an RSV vaccine (like Shingrix-style “shots”)?
No. Synagis is palivizumab, which works by providing ready-made antibodies. That’s different from an RSV vaccine, which trains the body’s immune system to make antibodies over time. Synagis is given on a schedule during RSV season to provide protection while antibodies are present [1].
Can children still get RSV if they receive Synagis?
Yes. Synagis is preventive and lowers risk, but it does not eliminate RSV infection entirely. Children who received Synagis can still become ill from RSV, so caregivers are generally advised to watch for symptoms and seek care when needed [1].
Where to look for official eligibility and dosing details?
Because eligibility and timing depend on local guidance and patient factors, the most reliable details come from the prescribing information and the RSV prevention recommendations your clinician follows [1].
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103586